title: HDR brachytherapy makes Cs-137 intracavitary therapy for cervix cancer a breach of good practice.
authors.affiliation: Medical College of Wisconsin, Radiation Oncology, Milwaukee 53226, USA. mike_gillin@qmail.radonc.mcw.edu
authors.forename: M T
authors.initials: MT
authors.lastname: Gillin
authors.forename: J R
authors.initials: JR
authors.lastname: Palta
mesh_terms: D001918:Brachytherapy / Q000009:adverse effects / Q000592:standards; D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011785:Quality Assurance, Health Care; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*; D014594:Uterine Neoplasms / Q000532:radiotherapy
chemical_list: D002588:Cesium Radioisotopes